BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp. BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW; TSX: BCT) is developing therapies to destroy cancer

02/24/2026

: The Data Safety Monitoring Board (DSMB) identified no safety concerns, and recommended continuation of BriaCell’s pivotal Phase 3 study in without modifications. Learn more: https://bit.ly/4aoDATy

02/19/2026

President and CEO Dr. William V. Williams shares insights into BriaCell and BriaPro’s asset purchase agreement for an exclusive soluble CD80 license. Learn more: https://bit.ly/3MxcYGY

02/18/2026

BriaCell (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXZL) (TSX: BCT) and BriaPro Therapeutics Corp. announced that they have entered into a definitive purchase agreement pursuant to which BriaPro has agreed to purchase BriaCell’s exclusive license to develop and commercialize Soluble CD80 as a biologic agent for the treatment of cancer and other associated assets. Find details: https://bit.ly/3MxcYGY

02/17/2026

BriaCell President and CEO Dr. William V. Williams commented on the fifth consecutive positive recommendation from Data Safety Monitoring Board (DSMB) for BriaCell's Phase 3 study in . Learn more: https://bit.ly/4aoDATy

02/17/2026

BriaCell (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXZL) (TSX: BCT) announced that the independent Data Safety Monitoring Board (DSMB) has issued its fifth consecutive positive recommendation following review of safety data from BriaCell’s pivotal Phase 3 Bria-ABC study of Bria-IMT plus immune checkpoint inhibitor (CPI) in patients with metastatic breast cancer. Find details: https://bit.ly/4aoDATy

02/12/2026

BriaCell's Phase 3 Bria-IMT™ clinical trial in metastatic breast cancer has been prominently and independently featured in the Nature Medicine Year In Review’s publication, “Eleven clinical trials that will shape medicine in 2026”.

Read the full article: https://briacell.com/media-coverage/

On , we stand with patients, families, researchers, and advocates around the globe working toward a future beyond cance...
02/04/2026

On , we stand with patients, families, researchers, and advocates around the globe working toward a future beyond cancer.

At BriaCell, we are a clinical stage immuno-oncology company that is developing an entirely new class of targeted to transform cancer care.

Discover how you can get involved: https://www.worldcancerday.org/

01/29/2026

ICYMI: BriaCell released new images highlighting resolution of metastatic breast cancer lesions in patients with orbital (eye), temporal lobe (brain), liver, and spinal involvement. Discover more: https://bit.ly/3LE1EZd

01/28/2026

BriaCell President & CEO Dr. William V. Williams comments on the new CD8 ImmunoPET images that verify the ability of the BriaCell treatment to activate CD8+ cytotoxic (“killer”) T cells and induce their infiltration into the cancerous tumors. Learn more: https://bit.ly/3LE1EZd

01/28/2026

BriaCell (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) released new images highlighting resolution of metastatic breast cancer lesions in patients with orbital (eye), temporal lobe (brain), liver, and spinal involvement. Survival details on these and other select patients in its Phase 2 study, along with comparable populations, were previously reported. Find details: https://bit.ly/3LE1EZd

01/27/2026

Nine of 25 BriaCell patients treated with Bria-IMT™ since 2022 remain alive >18-47 months post enrollment, markedly exceeding benchmarks reported for standard of care therapies in similar patient populations. Discover more: https://bit.ly/3NFaXIV

01/27/2026

Adam M. Brufsky, MD, PhD, FACP, Professor of Medicine at the University of Pittsburgh School of Medicine and Medical Director of the Magee-Women's Cancer Program stated, “This two-year overall survival data shows the possible therapeutic potential of Bria-IMT regimen for late-stage MBC, a very difficult-to-treat cancer. https://bit.ly/3NFaXIV

Address

2929 Arch Street, 3rd Floor
Philadelphia, PA
19104

Telephone

+18884856340

Website

Alerts

Be the first to know and let us send you an email when BriaCell Therapeutics Corp. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to BriaCell Therapeutics Corp.:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

BriaCell Therapeutics

Dedicated to enhance the lives of cancer patients who are facing limited therapeutic options, BriaCell Therapeutics Corp. (OTCQB: BCTXF; TSX: BCT.V)’s mission has been to develop novel immunotherapies, as the most cutting edge technology to fight cancer. Immunotherapies have become the forefront of the cancer treatments because they use the body’s immune system to destroy the cancer cells, offering higher levels of safety and efficacy than chemotherapy, with less likeliness of recurrence.

Designed by our team of scientists and clinicians, BriaCell’s proprietary whole-cell based technology platform continues to show its impressive potential to establish a new model for treating cancer patients. Our lead product candidate, Bria-IMT™ (SV-BR-1-GM), is a genetically engineered whole-cell based product candidate derived from a human breast cancer cell line. Bria-IMT™ is used in combination with multiple immune-modulators to powerfully trigger the immune system to recognize and eliminate cancerous cells.